Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team [Yahoo! Finance]
Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration [Yahoo! Finance]